MARX Biotech , Ltd. EBIT

The latest EBIT for 7731.TWO is $-230M as of June 2026. That compares with $520M in the prior-year period — down 143.8% year over year. That is below the Consumer Discretionary sector average of $2.8T. Investors often review this figure alongside MARX Biotech , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 7731.TWO's EBIT moved from $520M to $-230M — a 143.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in MARX Biotech , Ltd.'s operating scale or balance-sheet position.

Against Consumer Discretionary companies, 7731.TWO currently prints $-230M for EBIT, while the sector average sits near $2.8T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at MARX Biotech , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-230M for 7731.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Consumer Discretionary average is about $2.8T. Explore the charts below for those layers of context.

After noting 7731.TWO's EBIT ($-230M), review year-over-year change from $520M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.